Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  • STATUS
    Recruiting
  • End date
    Dec 22, 2023
  • participants needed
    590
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 17 November 2021
cancer
combination therapy
systemic therapy
estrogen
measurable disease
carcinoma
breast cancer
growth factor
squamous cell carcinoma
steroid therapy
x-rays
progesterone
cytotoxic chemotherapy
gemcitabine
pembrolizumab
epidermal growth factor receptor
EGFR
programmed cell death 1 ligand 1
human epidermal growth factor
adenocarcinoma
solid tumour
solid tumor
triple negative breast cancer
progesterone receptor
erbb2
epidermal growth factor
estrogen receptor
fallopian tube
lenvatinib
bladder cancer
line of therapy
mk-3475
cholangiocarcinoma
biliary cancer
extrahepatic cholangiocarcinoma
metastatic pancreatic cancer
biliary tract cancer
cancer vaccine
colorectal neoplasm
pancreatic cancers
combined modality therapy
cancer of the ovary
stereotactic biopsy
pancreatic ductal adenocarcinoma
breast ductal carcinoma

Summary

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

Details
Condition Pancreatic Cancer, Ovarian disorder, Colorectal Cancer, Rectal disorder, Pancreatic disorder, Breast Cancer, Biliary neoplasm, Ovarian Cancer, Glioblastoma Multiforme, Neoplasm of unspecified nature of digestive system, Gastropathy, Gastric Cancer, Diet and Nutrition, Chronic Diarrhea, Stomach Discomfort, Pancreatic Disorders, Skin Wounds, Chronic Shoulder Pain, Vaginal Atrophy, Adverse Effects, Drugs, Injection Port, Breast Cancer - HER2 Positive, Anal Dysplasia, Primary Immunodeficiency, Pediatric Health, Near-Sighted Corrective Surgery, Colon Cancer Screening, Rectal Disorders, Colon cancer; rectal cancer, Ovarian Function, Advanced Solid Tumors, Peripheral Arterial Occlusive Disease, Triple Negative Breast Cancer, Brain Function, Gastric Carcinoma, Recurrent Respiratory Papillomatosis, Recurrent Ovarian Cancer, Razor Bumps (Pseudofolliculitis Barbae), Urothelial Tract Cancer, Islet Ce417ll Cancer, Metastatic Triple-Negative Breast Cancer, Stomach Cancer, Biliary Tract Cancer, Digestive System Neoplasms, colorectal neoplasm, glioblastoma, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, gastric cancers, colorectal cancers, cancer of the pancreas, ovarian tumors, pancreatic cancers, cancer, pancreatic, cancer, colorectal, colorectal tumor, tumors, colorectal, biliary cancer
Treatment Pembrolizumab, Lenvatinib
Clinical Study IdentifierNCT03797326
SponsorMerck Sharp & Dohme Corp.
Last Modified on17 November 2021

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note